Application of MALDI-TOF MS for enumerating bacterial constituents of defined consortia

Abstract

Characterization of live biotherapeutic product (LBP) batches typically includes a measurement of viability, such as colony forming units (CFU). However, strain-specific CFU enumeration assays can be complicated by the presence of multiple organisms in a single product with similar growth requirements. To overcome specific challenges associated with obtaining strain-specific CFU values from multi-strain mixtures, we developed a method combining mass spectrometry-based colony identification with a traditional CFU assay. This method was assessed using defined consortia made from up to eight bacterial strains. Among four replicate batches of an eight-strain mixture, observed values differed from expected values by less than 0.4 log10 CFU among all strains measured (range of differences, -0.318 to + 0.267). The average difference between observed and expected values was + 0.0308 log10 CFU, with 95% limits of agreement from -0.347 to 0.408 (Bland–Altman analysis). To estimate precision, a single batch of eight-strain mixture was assayed in triplicate by three different users, for a total of nine measurements. Pooled standard deviation values ranged from 0.067 to 0.195 log10 CFU for the eight strains measured, and user averages did not differ significantly. Leveraging emerging mass-spectrometry-based colony identification tools, a novel method for simultaneous enumeration and identification of viable bacteria from mixed-strain consortia was developed and tested. This study demonstrates the potential for this approach to generate accurate and consistent measurements of up to eight bacterial strains simultaneously and may provide a flexible platform for future refinements and modifications. Key points • Enumeration of live biotherapeutics is essential for product quality and safety. • Conventional CFU counting may not differentiate between strains in microbial products. • This approach was developed for direct enumeration of mixed bacterial strains simultaneously.

Tannerella forsythia, Fusobacterium nucleatum, and Suspected Actinomyces Causing Massive Empyema: A Case Report

“…While not as accurate as gene sequencing, MALDI's speed and cost are more favorable. Proposed limitations of MALDI include a lack of anaerobic strains in the respective databases used [16][17][18]. Continued expansion of susceptibility testing for anaerobic databases would likely enhance MALDI's accuracy.…”

Nanobodies as potential tools for microbiological testing of live biotherapeutic products

“…The Bruker MALDI Biotyper (MBT) Smart system (Bruker Daltonics, Billerica MA) was utilized to differentiate L. crispatus 33820 and L. jensenii 115-3-CHN colonies grown on MRS agar plates as previously described (Coryell et al 2023 ). Briefly, L. crispatus 33820 and L. jensenii 115-3-CHN were added to the Main Spectra Profile (MSP) library according to the manufacturer’s instructions.…”

Treasures of Italian Microbial Culture Collections: An Overview of Preserved Biological Resources, Offered Services and Know-How, and Management

“…Various phenotypic screening tools based on biochemical properties, such as API ID32C and AuxaColor, are commercially available [33][34][35][36] as well as automated metabolic characterisation facilities, i.e., VITEK 2 and Biolog's Omnilog System [37,38]. Recently, MALDI-TOF mass spectrometry (based on the comparison of protein mass spectra with well-characterised reference strains included in reliable databases) is proving to be a commonly used methodology for microbial (mainly bacterial) identification, especially in the clinical fields but also in commercial sectors [39][40][41].…”